Phase 2 Completed N=14 Treatment

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Source: ClinicalTrials.gov NCT00961532 ↗

Enrolled (actual)

Serious AEs

14.3%

Results posted

Aug 2014

Primary outcomePrimary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014

Summary

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment	68	0.014 sig
SECONDARY Adverse Events : New Fever >=100.4F, Respiratory Distress or Pulmonary Edema on Chest Radiography, Rash, Hypotension (Systolic BP < 100 mm Hg or New Vasopressor Use or Increase in Vasopressor Dose by >25%)	2	—

Eligibility Criteria

Inclusion Criteria

Spontaneous intracerebral hemorrhage as documented by head CT scan
Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria

International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
History of von Willebrand disease
Pregnancy
Known hypersensitivity to DDAVP or desmopressin
Active cardiovascular disease or unstable angina
Hyponatremia or history of hyponatremia
Current or historical deep venous thrombosis or pulmonary embolism

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00961532). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.